Date: 2015-05-18
Type of information: R&D agreement
Compound: Nanobodies® against a target in multiple sclerosis
Company: Ablynx (Belgium) Genzyme (USA - MA), a Sanofi company (France)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Type agreement: R&D
Action mechanism:
Disease: multiple sclerosis
Details: * On May 18, 2015, Ablynx announced that it has entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate Nanobodies® against a target that plays an important role in multiple sclerosis (MS) and specifically aligns with Genzyme’s early-stage MS research programs involving neuroprotection and CNS repair. The neurodegeneration observed in MS is not directly targeted by existing treatments. Genzyme’s research efforts aim to address this unmet need by targeting the underlying causes of MS disease progression and by developing treatments to protect neurons and promote repair of CNS damage.
Under the terms of the agreement, Genzyme will have the right to perform in vitro and in vivo research with Ablynx’s Nanobodies in MS-relevant models in return for an exclusivity fee. Upon completion of these studies, Genzyme will have the option to negotiate a license agreement. Ablynx has already generated potent Nanobodies against the specific target of interest and confirmed their activity in preclinical models.
Financial terms:
Latest news:
